Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Century Therapeutics (IPSC) Amortization of Deferred Charges (2022 - 2023)

Century Therapeutics has reported Amortization of Deferred Charges over the past 2 years, most recently at $38000.0 for Q2 2023.

Quarterly Amortization of Deferred Charges fell 50.0% to $38000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $94000.0 through Dec 2023, down 68.46% year-over-year, with the annual reading at $94000.0 for FY2023, 68.56% down from the prior year.
Amortization of Deferred Charges was $38000.0 for Q2 2023 at Century Therapeutics, down from $56000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $77000.0 in Q3 2022 and troughed at $38000.0 in Q2 2023.